- National Medical Products Administration of China has approved AstraZeneca plc's AZN Imfinzi (durvalumab) to treat an aggressive type of lung cancer in adults.
- The approval comes for the 1st-line treatment of adult patients with extensive-stage small-cell lung cancer, combined with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).
- China's approval came after positive results from a late-stage trial, which showed that the drug, when used with chemotherapy, reduced the risk of death by 27% versus chemotherapy alone.
- Median overall survival stood at 13.0 months versus 10.3 months for chemotherapy alone.
- Price Action: AZN shares are up 0.70% at $56.39 during the premarket session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
